Rznomics (476830.KQ) — Stock Score Summary

Rznomics (476830.KQ) has a MoatMap StockRank of 5/100 based on Quality (36/100), Value (20/100), and Momentum (25/100) factor scores. The current signal is STRONG SELL.

Rznomics Inc. develops RNA based gene therapies for cancers and intractable diseases. Its development stage product candidates include RZ-001_immune therapy combination product, which is in Phase 1b/2a stage for treating Hepatocellular carcinoma; RZ-001 (GBM) that is in Phase 1/2a stage for...

Key Financial Metrics

Price$61.15
Market Cap$846M
Price/Book21.70
Return on Equity-176.3%
Return on Invested Capital-166.8%
Debt/Equity2.03
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-5K

Rznomics operates in the Biotechnology industry, part of the Healthcare sector (South Korea).

Frequently Asked Questions

What is Rznomics’s (476830.KQ) StockRank?
MoatMap’s StockRank for Rznomics (476830.KQ) is 5/100, with a Strong Sell signal. It is a composite of Quality (36), Value (20), and Momentum (25) factor ranks across MoatMap’s 19,000+ stock universe.
Does Rznomics have an economic moat?
Rznomics (476830.KQ) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Rznomics a buy, hold, or sell?
MoatMap’s current signal for Rznomics (476830.KQ) is Strong Sell, based on a StockRank of 5/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Rznomics in?
Rznomics (476830.KQ) operates in the Healthcare sector, specifically the Biotechnology industry (South Korea).
Browse all ranked stocks476830.KQ deep dive reportAI ChampionsHow we score stocksSense-check another stock